ORIC PHARMACEUTICALS, INC. Proceeds from Sale of Notes Receivable
ORIC PHARMACEUTICALS, INC. (ORIC) reported Proceeds from Sale of Notes Receivable of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-21.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfNotesReceivable · last filed 2022-03-21
- ORIC PHARMACEUTICALS, INC. proceeds from sale of notes receivable for the quarter ending 2020-12-31 was $0.00.
- ORIC PHARMACEUTICALS, INC. proceeds from sale of notes receivable for the quarter ending 2020-09-30 was $0.00.
- ORIC PHARMACEUTICALS, INC. proceeds from sale of notes receivable for the quarter ending 2020-06-30 was $0.00.
- ORIC PHARMACEUTICALS, INC. proceeds from sale of notes receivable for the quarter ending 2020-03-31 was $193.00K.
- ORIC PHARMACEUTICALS, INC. proceeds from sale of notes receivable for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- ORIC PHARMACEUTICALS, INC. proceeds from sale of notes receivable for fiscal 2020 was $193.00K.
- ORIC PHARMACEUTICALS, INC. proceeds from sale of notes receivable for fiscal 2018 was $17.00K.
| Period end | Proceeds from Sale of Notes Receivable 3 month | Proceeds from Sale of Notes Receivable 6 month | Proceeds from Sale of Notes Receivable 9 month | Proceeds from Sale of Notes Receivable 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-21 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $0.00 derived: sum of 2 quarters · filed 2022-03-21 | $0.00 derived: sum of 3 quarters · filed 2022-03-21 | $193.00K 10-K · filed 2022-03-21 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $193.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $193.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $193.00K 10-Q · filed 2021-05-06 | |||
| 2018-12-31 | $17.00K 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |